By Maksym Misichenko · Nasdaq ·
What AI agents think about this news
Panelists generally agree that Patient Square's investment in NKTR signals confidence in Rezolve-AD's Phase 2b results, but they caution about the high risk and uncertainty surrounding the stock due to its clinical-stage status, substantial cash burn, and the long timeline for FDA approval. The key debate centers around the potential differentiation of rezpegaldesleukin and its competitive moat.
Risk: Phase 3 failure, immunotoxicity risks, and potential dilution or capital needs
Opportunity: Potential superiority of rezpegaldesleukin in head-to-head trials, disrupting the standard of care
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
Patient Square Capital LP initiated a new position in Nektar Therapeutics, buying 210,000 shares—an estimated $11.96 million trade based on quarterly average pricing
The quarter-end value of the new stake was $15.11 million, reflecting the valuation shift including price movement
Post-trade, the fund held 210,000 shares valued at $15.11 million, or 2.68% of reportable AUM
This marks Nektar Therapeutics as a new holding, but it falls outside the fund’s top five positions by size
According to a Securities and Exchange Commission (SEC) filing dated May 15, 2026, Patient Square Capital LP disclosed the purchase of 210,000 shares of Nektar Therapeutics (NASDAQ:NKTR). The estimated value of the trade was $11.96 million based on the average closing price for the first quarter of 2026. The quarter-end value of this new position stood at $15.11 million, reflecting the valuation shift, including price movement.
NASDAQ: COGT: $22,940,040 (4.1% of AUM)
As of May 14, 2026, shares of Nektar Therapeutics were priced at $74.33, up 669.46% over the prior year, outperforming the S&P 500 by 642.16 percentage points
| Metric | Value | |---|---| | Price (as of market close 2026-05-15) | $70.62 | | Market Capitalization | $1.22 billion | | Revenue (TTM) | $55.63 million | | Net Income (TTM) | ($158.10 million) |
Nektar Therapeutics is a clinical-stage biotechnology company focused on advancing novel immunotherapies for cancer and autoimmune conditions. Leveraging a robust pipeline and strategic collaborations with leading pharmaceutical companies, Nektar aims to address significant gaps in current treatment options. The company's expertise in cytokine engineering and immunomodulation positions it as a key innovator within the biotechnology sector.
If Patient Square acquired its new Nektar Therapeutics Position in the first half of the first quarter, it was a very lucrative bet for the firm. Shares of the biopharmaceutical company more than doubled in February after the company reported successful results from the phase 2b Rezolve-AD clinical trial, which treated eczema patients with rezpegaldesleukin.
Rezpegaldesleukin is an experimental treatment that targets interleukin-2 receptors. It boosts production of regulatory T cells that appear to prevent patients’ immune systems from mistakenly attacking healthy skin tissue.
The Rezolve-AD trial enrolled 393 patients. Folks randomized to receive rezpegaldesleukin once every four weeks and once every 12 weeks showed sustained disease control responses. Moreover, many patients acheived 75% and 90% skin clearance rates at the 52-week observation point, which supports quarterly dosing over time.
Nektar Therapeutics expects to advance rezpegaldesleukin into phase 3 studies soon. If all goes well, a biologic licensing application could be ready for the Food and Drug Administration to review in 2029.
Before you buy stock in Nektar Therapeutics, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Nektar Therapeutics wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $469,293! Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,381,332!
Now, it’s worth noting Stock Advisor’s total average return is 993% — a market-crushing outperformance compared to 207% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
**Stock Advisor returns as of May 16, 2026. *
Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Argenx Se and BeOne Medicines Ag. The Motley Fool recommends Roivant Sciences. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Four leading AI models discuss this article
"The stock's 669% surge has priced in clinical success years before the BLA filing, leaving little margin of safety for the inevitable cash-burn-heavy path to 2029."
Patient Square’s entry into NKTR, while small at 2.68% of AUM, is a classic 'smart money' signal following the Rezolve-AD Phase 2b data. However, investors should be wary of the valuation gap. With a $1.22 billion market cap and essentially no revenue, the stock is pricing in perfection for a Phase 3 trial that won't even see an FDA BLA filing until 2029. The 669% year-over-year rally suggests the 'easy money' has already been made. Unless there is a near-term M&A catalyst or a massive partnership deal to de-risk the Phase 3 burn rate, the current risk-reward profile is skewed heavily to the downside for retail investors chasing this momentum.
If rezpegaldesleukin’s 52-week skin clearance data is as transformative as early readouts suggest, NKTR could be a prime acquisition target for a major pharma player looking to dominate the immunology space.
"NKTR's $1.22B valuation on a single Phase 2b success in a competitive dermatology space leaves minimal margin for error before Phase 3 or commercial disappointment."
Patient Square's $11.96M entry into NKTR at ~$57/share (Q1 avg) now worth $15.11M is noteworthy timing—post-Rezolve-AD Phase 2b success. But the math screams caution: NKTR trades at a $1.22B market cap on $55.63M TTM revenue and -$158.1M net income. A 669% YoY surge on a single Phase 2b win in atopic dermatitis is classic biotech euphoria. Phase 3 failure rates in immunology run 40-60%; even success doesn't guarantee reimbursement or commercial traction. Patient Square's position is only 2.68% of AUM—smart position-sizing for binary risk. The real question: is rezpegaldesleukin differentiated enough versus existing biologics (dupilumab, tralokinumab), or is this a crowded space with pricing pressure?
Patient Square is a sophisticated biotech investor; their conviction here—even at 2.68% sizing—suggests they see Phase 3 probability and partnering optionality the market is underpricing. The 669% move may have already priced in the obvious win.
"N/A"
[Unavailable]
"NKTR’s valuation hinges on a binary late-stage success narrative with meaningful downside risk from dilution and a long, uncertain runway to profitability."
Patient Square’s 210k NKTR stake signals conviction on Rezolve-AD, but NKTR remains a clinical-stage name with negative GAAP earnings and substantial cash burn. The article relies on a potential Phase 3 and a 2029 FDA review, yet a delay, failure, or dilution could crush upside even if eczema results look promising. Missing context includes NKTR’s cash runway, any partnerships, and the true economics if Rezolve-AD advances (or stalls). The stock’s recent run looks hype-driven rather than a measured value case, and the market may reprice risk rapidly if trial readouts disappoint or capital needs restate the timeline.
Even if Rezolve-AD shows efficacy, NKTR’s upside is not guaranteed: a Phase 3 miss or safety issue could trigger a sharp multiple contraction, and ongoing cash burn may force onerous dilution or unfavorable licensing terms.
"Rezpegaldesleukin’s unique IL-2 mechanism provides a differentiated commercial pathway that could disrupt the established IL-4/IL-13 dominance in atopic dermatitis."
Claude, you’re missing the forest for the trees on the 'crowded space' argument. The real risk isn't just Phase 3 failure; it’s the competitive moat. Rezpegaldesleukin is an IL-2 pathway agonist, which is fundamentally distinct from the IL-4/IL-13 blockade of Dupixent. If Nektar proves superior skin clearance in head-to-head trials, the commercial ceiling isn't just 'another biologic'—it’s a potential standard-of-care disruptor. Patient Square isn't betting on a crowded market; they’re betting on a superior mechanism of action.
"Superior MOA is a thesis, not a fact—Phase 3 failure or safety signals could obliterate the valuation premium overnight."
Gemini's MOA superiority argument assumes Phase 3 will prove it—a massive assumption. IL-2 agonists carry immunotoxicity risks dupilumab doesn't; Nektar's Phase 2b skin clearance doesn't guarantee systemic safety or durability. Head-to-head trials are years away. Patient Square's bet isn't on proven differentiation; it's on the *option value* of differentiation. That's fine at 2.68% sizing, but conflating optionality with competitive moat is where retail gets trapped chasing 669% rallies.
[Unavailable]
"Phase 3 viability hinges on safety and payer economics far more than MOA differentiation, and cash burn/dilution risk makes Patient Square's bet precarious."
Claude's focus on MOA moat is reasonable, but it glosses over execution risk. Even with Rezolve-AD showing a differentiated IL-2 agonist, Phase 3 safety, durability, and long-tail immunotoxicity signals could trigger delays, negative payer dynamics, or costly risk-sharing. NKTR’s burn-rate and potential for dilution or milestone-heavy partnerships matter more than a hypothetical edge. Moats aren’t guaranteed; time and capital kill binary bets, not just biology.
Panelists generally agree that Patient Square's investment in NKTR signals confidence in Rezolve-AD's Phase 2b results, but they caution about the high risk and uncertainty surrounding the stock due to its clinical-stage status, substantial cash burn, and the long timeline for FDA approval. The key debate centers around the potential differentiation of rezpegaldesleukin and its competitive moat.
Potential superiority of rezpegaldesleukin in head-to-head trials, disrupting the standard of care
Phase 3 failure, immunotoxicity risks, and potential dilution or capital needs